Soltero-Rivera Maria, Hart Sterling, Blandino Andrew, Vapniarsky Natalia, Arzi Boaz
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.
Department of Statistics, University of California, Davis, Davis, CA, United States.
Front Vet Sci. 2023 Apr 14;10:1171922. doi: 10.3389/fvets.2023.1171922. eCollection 2023.
Mesenchymal stromal cells (MSC) therapy has emerged as a potential treatment option for refractory FCGS. However, there is a lack of long-term data on the use of MSC therapy in cats. This study aimed to evaluate the long-term safety and efficacy of MSC therapy for FCGS and investigate potential factors associated with treatment outcomes.
This study was a retrospective evaluation of 38 client-owned cats with refractory FCGS who received MSC therapy. Medical records, histopathology, and the Stomatitis Activity Disease Index (SDAI) were reviewed. Correlations of the long-term follow-up success rates with SDAI and cell line type used were conducted. A client survey was also performed to assess side effect occurrence, quality-of-life following treatment, and overall treatment satisfaction.
Long-term follow-up ranged from 2 to 9 years post-MSC treatment. The overall positive response rate to MSC treatment was 65.5%, with 58.6% of cats exhibiting permanent improvement or cure. Adverse effects occurring during or immediately after treatment were noted in 34.2% of cases, the majority being transient, self-resolving transfusion-like reactions. No long-term adverse events were noted. No significant correlation in outcome was detected between allogeneic and autologous MSC treatment ( = 0.871) or the severity of the SDAI at entry ( = 0.848) or exit ( = 0.166), or the delta SDAI between entry and exit ( = 0.178). The status 6 months (none to partial improvement vs. substantial improvement to resolution) post-therapy was a predictor of long-term response (value of < 0.041). Most clients were satisfied with the treatment and outcomes, with 90.6% willing to pursue treatment again, given a similar situation.
The results of this study support the use of both autologous and allogeneic MSC as an efficacious and safe therapeutic option for refractory FCGS.
间充质基质细胞（MSC）疗法已成为难治性口炎型猫慢性牙龈炎和口炎（FCGS）的一种潜在治疗选择。然而，关于猫使用MSC疗法的长期数据尚缺乏。本研究旨在评估MSC疗法治疗FCGS的长期安全性和有效性，并调查与治疗结果相关的潜在因素。
本研究是对38只接受MSC疗法的难治性FCGS客户拥有的猫进行的回顾性评估。回顾了病历、组织病理学和口炎活动疾病指数（SDAI）。对长期随访成功率与SDAI和所用细胞系类型之间的相关性进行了分析。还进行了一项客户调查，以评估副作用的发生情况、治疗后的生活质量和总体治疗满意度。
MSC治疗后长期随访时间为2至9年。MSC治疗的总体阳性反应率为65.5%，58.6%的猫表现出永久性改善或治愈。34.2%的病例在治疗期间或治疗后立即出现不良反应，大多数为短暂的、可自行缓解的类似输血反应。未观察到长期不良事件。在同种异体和自体MSC治疗之间（P = 0.871）、入组时SDAI的严重程度（P = 0.848）或退出时（P = 0.166），或入组和退出之间的SDAI差值（P = 0.178），均未检测到结果的显著相关性。治疗后6个月的状态（无改善至部分改善与显著改善至治愈）是长期反应的预测指标（P值 < 0.041）。大多数客户对治疗和结果感到满意，90.6%的客户表示在类似情况下愿意再次接受治疗。
本研究结果支持将自体和同种异体MSC用作难治性FCGS的有效且安全的治疗选择。
